Xenon Pharmaceuticals Inc. (XENE)
| Previous close | 35.03 |
| Open | 35.13 |
| Bid | 35.21 x 1000 |
| Ask | 35.35 x 1000 |
| Day's range | 34.97 - 35.54 |
| 52-week range | 31.79 - 43.75 |
| Volume | |
| Avg. volume | 318,892 |
| Market cap | 2.257B |
| Beta (5Y monthly) | 1.34 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.50 |
| Earnings date | 06 Nov 2023 - 10 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 52.64 |
GlobeNewswireXenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit to be held on September 20, 2023. Company Fireside Chat Presentation Details: Date:Wednesday, September 20, 2023 Time:4:20 pm Eastern Time Webcast:Register here Presenters:Ian Mortimer, President and Chief Executive OfficerSherry Aul
- GlobeNewswire
Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder
Live broadcast of webinar on Tuesday, September 19 beginning at 11:30 am ETVANCOUVER, British Columbia, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will host an investor webinar with two leading key opinion leaders (KOLs) focused on major depressive disorder. Webinar:“XEN1101 and the Major Depressive Disorder (MDD) Landscape: A Discussion with KOLs”Date:Tuesday, September 19, 2023Time
- GlobeNewswire
Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress
New interim data from ongoing Phase 2b X-TOLE open-label extension demonstrates improvement in overall quality-of-life (QoL) when compared to baseline Clinically important improvements seen for all patients across important subscales of Seizure Worry, Social Functioning and Medication Effects and for seizure free patients across all QoL subscales Oral presentations showcase Phase 3 clinical trials in focal onset seizures and primary generalized tonic-clonic seizures VANCOUVER, British Columbia,
